

FIG Insurances Equity – China

Overweight(V)

Target price HKD	34
Share price HKD	25.95
Potential return (%)	31

Note: Potential return equals the percentage difference between the current share price and the target price

Performance	1M	3M	12M	
Absolute (%) Relative^ (%)	-3.9 -2.3	29.8 23.7	123.6 99.8	
Index^	HAN	IG SENG	INDEX	
RIC Bloomberg	0966.HK 0966 HK			
Market cap (USDm) Market cap (HKDm)			10,401 80,653	
Free float (%)			31	

Note: (V) = volatile (please see disclosure appendix)

26 March 2015

James E. Garner*, CFA Head of Asian Insurance Equity Research The Hongkong and Shanghai Banking Corporation Limited

+852 2822 4321 james.e.garner@hsbc.com.hk

Jianwei Yang*

Analyst The Hongkong and Shanghai Banking Corporation Limited +852 2914 9575 jianwei.yang@hsbc.com.hk

Bolun Tang*

Analyst The Hongkong and Shanghai Banking Corporation Limited +852 2822 2895 bo.lun.tang@hsbc.com.hk

View HSBC Global Research at: http://www.research.hsbc.com

*Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/qualified pursuant to FINRA regulations

Issuer of The Hongkong and Shanghai report: Banking Corporation Limited

Disclaimer & Disclosures

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it

China Taiping (966 HK)

OW(V): Raise TP by 10% after better-than-expected FY14

- CTIH's highest-of-peers 37% NBV growth beat lofty consensus expectations by 11%
- Group refrained from providing any new three year plan targets after successfully hitting all 2011-14 plan targets
- Reiterate OW(V) rating on CTIH shares, which offer 31% potential return to revised TP of HKD34 (was HKD31 TP)

What we liked: (i) Life NBV was 11% above consensus and 6% above our estimate. The highest-of-peers 37% increase in NBV (1H:+44%, 2H +30%) was driven by a 48% rise in APE and 1.8ppt fall in margins. Three out of four Chinese insurers have reported margin declines; (ii) group EV was 9% above consensus, having risen 66% YoY. Life EV, which contributed 79% of group EV, rose 44% of which 38%pts pertained to positive investment variances. China Taiping made no changes to its EV assumption set although its 5.3% investment return looks higher vs China Life (5.2%), Ping An (4.75%), and New China Life (5.0%); (iii) net income was 6% above company guidance given on 21 January and 7% above consensus; (iv) Book Value was 3% above consensus having risen 52% HoH; (v) life solvency ratio was 275%, comfortably above 100-150% CIRC prescribed minimum; and (vii) average APE per agent rose 9% Y-o-Y.

<u>What we disliked:</u> (i) sadly, management refrained from communicating any new three year targets following successful execution of 2011-14 plan. The group did allude to expanding market share in addition to improving cost efficiency, agent quality and business quality relative to industry. Taiping does have work to do on improving business quality with its 23% NBV margin far below peers; (ii) missed target of 140k Agents (FY14: 133,734). While Taiping claims that the Agent target slippage was attributable to high assessment standards, we suspect some of the miss was due to the roll-off of 18mth fixed salary contracts and aggressive peer recruitment in 2H; (iii) persistency ratios on 13mth basis deteriorated; (iv) financial disclosure needs improvement. We need NBV by channel (Q&A revealed 98.5% was Agent), group solvency ratio and free surplus movement; (v) P&C solvency ratio can best be described as adequate at 174%; and (vii) higher risk Non-Standard Assets (NSA) increased from 12% to 17% of investment.

Reiterate OW(V) and increase TP by 10% to HKD34, which offers 31% potential

return. The increase in TP is driven by the better-than-expected FY14 EV & NBV coupled with positive financial mark-to-market impact.



Financials & valuation

P&L summary (HKDm)						
Year to	12/2014a	12/2015e	12/2016e	12/2017e		
Life	4,531	5,362	6,369	7,799		
Reinsurance	481	520	612	722		
Non-life	1,220	1,093	1,195	1,431		
Other businesses	266	241	354	504		
Profit before tax	6,614	7,346	8,683	10,643		
Income tax	(1,740)	(1,836)	(2,171)	(2,661)		
Net profit	4,874	5,509	6,513	7,982		
Minority interests	(832)	(1,001)	(1,189)	(1,456)		
Equity holders of the parent	4,042	4,508	5,323	6,526		

Operational metrics				
Year to	12/2014a	12/2015e	12/2016e	12/2017e
Reported NBV	4,326	5,104	6,024	7,108
Reported Life NBV growth	37.4%	18.0%	18.0%	18.0%
Reported Life NBV margin	23.0%	22.8%	22.7%	22.5%
Rebased NBV	4,326	5,104	6,024	7,108
Rebased Life NBV margin	23.0%	22.8%	22.7%	22.5%
Life RoEV	12.1%	17.2%	16.4%	16.5%
Rebased Life NBV as % Life EV B/F	9.5%	7.8%	7.8%	8.0%
Reinsurance NPE growth	70%	14%	20%	20%
Reinsurance ROE	17%	14%	11%	12%
Reins reported COR	61.6%	77.5%	101.0%	101.0%
P&C NPE growth	30%	15%	15%	15%
P&C ROE	-13.7%	-10.1%	-6.8%	-6.4%
P&C reported COR	99.8%	99.8%	100.3%	100.3%
Net investment yield	5.0%	5.2%	5.2%	5.2%

Embedded value (HKDm)							
Year to	12/2014a	12/2015e	12/2016e	12/2017e			
Adjusted net worth	24,819	27,378	29,851	32,619			
Gross VIF	46,329	59,567	71,739	86,220			
Cost of capital	(6,135)	(10,126)	(12,196)	(14,657)			
Expense overrun	0	0	0	0			
Life EV - Reported	65,553	76,819	89,394	104,182			
Discount rate rebasing	0	0	0	0			
Life EV (100%)	65,553	76,819	89,394	104,182			
Minorities (49.05%)	(16,323)	(19,128)	(22,259)	(25,941)			
Life EV (50.05%)	49,230	57,691	67,135	78,241			
Other ANW	13,202	16,724	20,917	26,212			
Group EV	62,432	74,415	88,052	104,452			

China Taiping

Group valuation metrics						
Year to	12/2014a	12/2015e	12/2016e	12/2017e		
P/EV Group	1.3x	1.1x	0.9x	0.8x		
- Group RoEV	37%	19%	18%	19%		
P/ Tangible NAV	2.0x	1.8x	1.5x	1.3x		
- RoTŇAV	13%	10%	11%	11%		
P/ book value	2.0x	1.8x	1.5x	1.3x		
- RoE	13%	10%	11%	11%		
P/E	18x	18x	15x	13x		
Dividend yield	0%	0%	0%	0%		

Per share data (HKD)				
Year to	12/2014a	12/2015e	12/2016e	12/2017e
EV group	19.77	23.57	27.88	33.08
- growth	29%	19%	18%	19%
TNAV	12.89	14.81	16.93	19.48
- growth	47%	15%	14%	15%
Book value	12.89	14.81	16.93	19.48
- growth	47%	15%	14%	15%
EPS	1.47	1.43	1.69	2.07
- growth	75%	-3%	18%	23%
DPS	0.00	0.00	0.00	0.00
- payout ratio	0%	0%	0%	0%

Issuer information				
Market Cap (HKDm)			80,653	
Market Cap (USDm)			10,401	
Free Float			31%	
Valuation changes	New	Old	Change	
Avg ROEV 2015 -17e	18.7%	19.0%	-0.3%	
Sustainable growth	5%	5%	0%	
Cost of equity	12.9%	12.9%	0%	
Implied multiple (x)	1.73x	1.76x	-0.04x	
EV p/s	23.6	21.3	11%	
Fair value end 2015e	40.7	37.6	8.3%	
12M Fair Value	41.9	38.5	9%	
Asset risk	(4.4)	(4.4)	-2%	
Dividend	Ó	Ó	0%	
Valuation discount	10%	10%	0%	
H target price - HKD	34.0	31.0	10%	



Note: price at close of 26 Mar 2015



Exhibit 1: Key summaries

HKDm unless otherwise	FY12	FY13	FY14	Change FY14/13	vs. HSBC Beat/ Miss, %	vs. Consensus Beat/ Miss, %	Change % 1H14	YoY 2H14
Net profit share'rs	1,316	1,653	4,042	145%	6%	7%	179%	119%
EPS (HKD)	0.70	0.75	1.44	93%	5%	7%	117%	72%
Dividend per share (HKD)	0.00	0.00	0.00	Unchanged	0%	0%	0%	0%
FYP	18,426	32,463	41,326	27%			23%	39%
Protection as % Individual FY Regular	34%	37%	30%	-7%			3%	-25%
New RP as % FYP	39%	32%	39%	7%			3%	15%
APE	8,383	12,704	18,818	48%	21%		32%	73%
- Individual	4,424	8,245	12,937	57%			34%	86%
- Bancassurance	3,499	3,925	5,300	35%			30%	47%
- Other	459	533	582	9%			14%	5%
Reported NBV	2,304	3,148	4,326	37%	6%	11%	44%	30%
NBV/ APE reported margin	27.5%	24.8%	23.0%	-1.8%	-3.4%		2.0%	-7.3%
Avg. # agents	51,962	85,328	123,265	44%			35%	11%
FYP per mth per avg. # agent (RMB)	7,156	10,715	9,915	-7%			4%	16%
APE per mth per avg. # agent (RMB)	7,095	8,052	8,746	9%			-1%	68%
P&C combined ratio	99.8%	99.8%	99.8%	0.0%	1.2%	0.5%	0.1%	-2.8%
Reins. Combined ratio	106.9%	96.5%	89.3%	-7.2%	-8.2%			
Equities as % Total Investment	7.7%	6.5%	10.1%	3.5%	3.7%		0.5%	3.5%
Net investment vield	3.3%	3.6%	4.6%	1.0%	0.0%		-1.2%	
Total investment yield	3.6%	5.1%	5.8%	0.7%	0.6%		0.4%	
Life	547	1,402	4,531	223%	3%		487%	118%
P&C	891	704	1,220	73%	27%		37%	143%
Reinsurance	131	434	481	11%	-11%		35%	-14%
Other	182	17	382	2208%	-281%		-287%	-1334%
Pre-tax	1,751	2,557	6,614	159%	16%		179%	142%
Persistency ratio - 13mths	· · · ·							
- Individual	92.3%	92.9%	92.6%	-0.3%				
- Bancassurance	92.9%	92.3%	91.1%	-1.2%				
Persistency ratio - 25mths								
- Individual	88.5%	88.4%	88.7%	-0.3%				
- Bancassurance	90.2%	89.6%	88.5%	1.1%				
				Change	vs. HSBC	vs. Consensus	Change %	HoH
HKDm unless otherwise	FY12	FY13	FY14	FY14/13	Beat/ Miss, %	Beat/ Miss, %	1H14	2H14
Total shareholders funds	16,308	21,421	35,993	68%	-3%	3%	11%	52%
Group embedded value (Owners')	22,172	37,537	62,432	66%	12%	9%	19%	40%
Life embedded value	29,286	45,390	65,553	44%	1%	8%	14%	26%
Risk discount rate assumption	11.0%	11.0%	11.0%	Unchanged				
Investment return assumption	4.75%	5.30%	5.30%	Unchanged				
Life solvency ratio	164%	166%	275%	109%	4%		25%	84%
P&C solvency ratio	163%	166%	174%	-8%	-8%		30%	-22%
No. life agents	57,860	112,796	133,734	19%	-4%		0%	19%

Source: Company data, Bloomberg, HSBC

Valuation and risks

We derive our share target price of HKD34 by using a P/EV valuation methodology net of a 10% disclosure discount and 10% asset risk discount. We calculate a fair P/EV multiple of 1.7x using a Gordon Growth Model formula, where we input a sustainable ROEV of 18.7% (determined by the average of our FY15-17 forecast for ROEV), a terminal growth rate of 5%, and a risk discount rate of 12.9%. Under our research model, for stocks with a volatility indicator, the Neutral band is 10 percentage points above and below the hurdle rate for China stocks of 9%. Our target price of HKD34 implies a potential return of 31%, which is above the Neutral band of our model; therefore, we are reiterating our Overweight (V) rating on China Taiping. Potential return equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated. Key downside risks to our Overweight (V) rating include management team's remaining prioritisation of volume over value creation, increased market awareness of group's use of double leverage and high losses from subscale reinsurance business.



Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), and/or strategist(s) who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and/or any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: James Garner, Jianwei Yang and Bolun Tang

Important disclosures

Equities: Stock ratings and basis for financial analysis

HSBC believes that investors utilise various disciplines and investment horizons when making investment decisions, which depend largely on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations. Given these differences, HSBC has two principal aims in its equity research: 1) to identify long-term investment opportunities based on particular themes or ideas that may affect the future earnings or cash flows of companies on a 12 month time horizon; and 2) from time to time to identify short-term investment opportunities that are derived from fundamental, quantitative, technical or event-driven techniques on a 0-3 month time horizon and which may differ from our long-term investment rating. HSBC has assigned ratings for its long-term investment opportunities as described below.

This report addresses only the long-term investment opportunities of the companies referred to in the report. As and when HSBC publishes a short-term trading idea the stocks to which these relate are identified on the website at www.hsbcnet.com/research. Details of these short-term investment opportunities can be found under the Reports section of this website.

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings and other considerations. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations. Investors should carefully read the definitions of the ratings used in each research report. In addition, because research reports contain more complete information concerning the analysts' views, investors should carefully read the entire research report and should not infer its contents from the rating. In any case, ratings should not be used or relied on in isolation as investment advice.

Rating definitions for long-term investment opportunities

Stock ratings

HSBC assigns ratings to its stocks in this sector on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The price target for a stock represents the value the analyst expects the stock to reach over our performance horizon. The performance horizon is 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, must exceed the required return by at least 5 percentage points over the next 12 months (or 10 percentage points for a stock classified as Volatile*). For a stock to be classified as Underweight, the stock must be expected to underperform its required return by at least 5 percentage points over the next 12 months (or 10 percentage points for a stock stock between these bands are classified as Neutral.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation of coverage, change of volatility status or change in price target). Notwithstanding this, and although ratings are subject to ongoing management review, expected returns will be permitted to move outside the bands as a result of normal share price fluctuations without necessarily triggering a rating change.




*A stock will be classified as volatile if its historical volatility has exceeded 40%, if the stock has been listed for less than 12 months (unless it is in an industry or sector where volatility is low) or if the analyst expects significant volatility. However, stocks which we do not consider volatile may in fact also behave in such a way. Historical volatility is defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility has to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.

Rating distribution for long-term investment opportunities

As of 26 March 2015, the distribution of all ratings published is as follows:				
Buy	41%	(30% of these provided with Investment Banking Services)		
Hold	39%	(27% of these provided with Investment Banking Services)		
Sell	20%	(20% of these provided with Investment Banking Services)		

Share price and rating changes for long-term investment opportunities



From	То	Date
Neutral (V)	Overweight (V)	30 August 2012
Overweight (V)	Neutral (V)	24 February 2013
Neutral (V)	Overweight (V)	15 May 2013
Target Price	Value	Date
Price 1	13.30	03 July 2012
Price 2	15.20	30 August 2012
Price 3	17.10	24 February 2013
Price 4	14.91	19 March 2013
Price 5	15.10	25 April 2013
Price 6	14.72	09 May 2013
Price 7	15.20	15 May 2013
Price 8	15.10	07 July 2013
Price 9	16.15	27 August 2013
Price 10	22.80	21 November 2013
Price 11	23.75	05 March 2014
Price 12	22.80	06 June 2014
Price 13	23.75	12 August 2014
Price 14	21.85	13 October 2014
Price 15	25.00	13 November 2014
Price 16	29.00	19 January 2015
Price 17	31.00	09 March 2015

Source: HSBC



HSBC & Analyst disclosures

Disclosure checklist						
Company	Ticker	Recent price	Price Date	Disclosure		
CHINA TAIPING INSURANCE	0966.HK	25.95	26-Mar-2015	1, 5, 6, 7		

```
Source: HSBC
```

- 1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 28 February 2015 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- 5 As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- 6 As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.
- 7 As of 31 January 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.
- 11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments (including derivatives) of companies covered in HSBC Research on a principal or agency basis.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research.

Additional disclosures

- 1 This report is dated as at 26 March 2015.
- 2 All market data included in this report are dated as at close 26 March 2015, unless otherwise indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.



Disclaimer

* Legal entities as at 30 May 2014

¹UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Bank Canada, Toronto; HSBC Bank, Paris Branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Madrid, Milan, Stockholm, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, SHSC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch Issuer of report The Hongkong and Shanghai Banking Corporation Limited Level 19, 1 Queen's Road Central Hong Kong SAR Telephone: +852 2843 9111 Fax: +852 2596 0200 Website: www research hsbc com

This document has been issued by The Hongkong and Shanghai Banking Corporation Limited ("HSBC") in the conduct of its Hong Kong regulated business for the information of its institutional and professional investor (as defined by Securities and Future Ordinance (Chapter 571)) customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority. All enquires by recipients in Hong Kong must be directed to your HSBC contact in Hong Kong. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Division of HSBC only and are subject to change without notice. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch "representative in respect of any matters arising from, or in connection with this report. In Australia, this publication has been distributed by The Hongkong and Shanghai Limited (AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been Shanghai Banking Corporation I mited Singapore and Shanghai in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or parti

In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. It may not be further distributed in whole or in part for any purpose. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea.

In Canada, this document has been distributed by HSBC Bank Canada and/or its affiliates. Where this document contains market updates/overviews, or similar materials (collectively deemed "Commentary" in Canada although other affiliate jurisdictions may term "Commentary" as either "macro-research" or "research"), the Commentary is not an offer to sell, or a solicitation of an offer to sell or subscribe for, any financial product or instrument (including, without limitation, any currencies, securities, commodities or other financial instruments).

© Copyright 2015, The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited. MICA (P) 157/06/2014, MICA (P) 136/02/2015 and MICA (P) 041/01/2015